Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention
Source abstract
Abstract
Abstract Macrophages are one of the most abundant non‐malignant cells in the tumor microenvironment, playing critical roles in mediating tumor immunity. As important innate immune cells, macrophages possess the potential to engulf tumor cells and present tumor‐specific antigens for adaptive antitumor immunity induction, leading to growing interest in targeting macrophage phagocytosis for cancer immunotherapy. Nevertheless, live tumor cells have evolved to evade phagocytosis by macrophages via the extensive expression of anti‐phagocytic molecules, such as CD47. In addition, macrophages also rapidly recognize and engulf apoptotic cells (efferocytosis) in the tumor microenvironment, which inhibits inflammatory responses and facilitates immune escape of tumor cells. Thus, intervention of macrophage phagocytosis by blocking anti‐phagocytic signals on live tumor cells or inhibiting tumor efferocytosis presents a promising strategy for the development of cancer immunotherapies. Here, the regulation of macrophage‐mediated tumor cell phagocytosis is first summarized, followed by an overview of strategies targeting macrophage phagocytosis for the development of antitumor therapies. Given the potential off‐target effects associated with the administration of traditional therapeutics (for example, monoclonal antibodies and small molecule inhibitors), the opportunity for nanomedicine in macrophage phagocytosis intervention is highlighted.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Phagocytosis and Immune Regulation · SARS-CoV-2 and COVID-19 Research · COVID-19 Clinical Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA
International Institutes of Medicine the Fourth Affiliated Hospital of Zhejiang University School of Medicine Zhejiang University Yiwu 322000 China
Department of Pharmacology and Department of Gastroenterology of the Second Affiliated Hospital of School of Medicine Zhejiang University Hangzhou 310058 China
Funding
National Institutes of Health
References (100+)
Show source-provided references
1. 10.1038/nrd213710.1038/nrd2137 ↗
2. 10.1038/nm.339410.1038/nm.3394 ↗
3. 10.1152/physrev.1996.76.1.6910.1152/physrev.1996.76.1.69 ↗
4. 10.1016/j.ccr.2012.02.02210.1016/j.ccr.2012.02.022 ↗
5. 10.1038/s41573-018-0004-110.1038/s41573-018-0004-1 ↗
6. 10.1038/nrclinonc.2016.21710.1038/nrclinonc.2016.217 ↗
7. 10.1016/j.cmet.2019.06.00110.1016/j.cmet.2019.06.001 ↗
8. 10.1016/j.ccr.2013.02.01310.1016/j.ccr.2013.02.013 ↗
9. 10.1038/s41577-019-0127-610.1038/s41577-019-0127-6 ↗
10. 10.1016/j.it.2015.02.00410.1016/j.it.2015.02.004 ↗
11. 10.1016/j.it.2019.02.00310.1016/j.it.2019.02.003 ↗
12. 10.1038/nri244810.1038/nri2448 ↗
13. 10.1146/annurev.immunol.23.021704.11581610.1146/annurev.immunol.23.021704.115816 ↗
14. 10.1038/onc.2017.26110.1038/onc.2017.261 ↗
15. 10.1038/nm.333710.1038/nm.3337 ↗
16. 10.1038/nature2140910.1038/nature21409 ↗
17. 10.1038/nrd.2018.16910.1038/nrd.2018.169 ↗
18. 10.1016/j.immuni.2016.02.02610.1016/j.immuni.2016.02.026 ↗
19. 10.1038/s41568-019-0183-z10.1038/s41568-019-0183-z ↗
20. 10.1056/NEJMoa120069410.1056/NEJMoa1200694 ↗
21. 10.1186/s12885-019-5380-310.1186/s12885-019-5380-3 ↗
22. 10.1056/NEJMoa161349310.1056/NEJMoa1613493 ↗
23. 10.1126/scitranslmed.aad711810.1126/scitranslmed.aad7118 ↗
24. 10.1016/S1470-2045(19)30413-910.1016/S1470-2045(19)30413-9 ↗
25. 10.1056/NEJMoa171212610.1056/NEJMoa1712126 ↗
26. 10.2174/13816128244519041615491710.2174/138161282445190416154917 ↗
27. 10.1158/2159-8290.CD-15-056310.1158/2159-8290.CD-15-0563 ↗
28. 10.1038/s41573-018-0007-y10.1038/s41573-018-0007-y ↗
29. 10.4049/jimmunol.174.4.200410.4049/jimmunol.174.4.2004 ↗
30. 10.1182/blood.V94.11.363310.1182/blood.V94.11.3633 ↗
31. 10.1038/s41587-020-0520-510.1038/s41587-020-0520-5 ↗
32. 10.1146/annurev.cellbio.20.010403.10275510.1146/annurev.cellbio.20.010403.102755 ↗
33. 10.1016/j.coi.2012.01.01010.1016/j.coi.2012.01.010 ↗
34. 10.1038/s41577-019-0167-y10.1038/s41577-019-0167-y ↗
35. 10.1186/s12943-019-1022-210.1186/s12943-019-1022-2 ↗
36. 10.1007/s00281-018-0698-510.1007/s00281-018-0698-5 ↗
37. 10.1096/fj.04-2747rev10.1096/fj.04-2747rev ↗
38. 10.1021/acsnano.8b0589310.1021/acsnano.8b05893 ↗
39. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
40. 10.1021/acs.nanolett.8b0234010.1021/acs.nanolett.8b02340 ↗
41. 10.1002/adma.20180830310.1002/adma.201808303 ↗
42. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
43. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
44. 10.3389/fimmu.2019.0199810.3389/fimmu.2019.01998 ↗
45. 10.1002/adfm.20180576010.1002/adfm.201805760 ↗
46. 10.7150/thno.3756810.7150/thno.37568 ↗
47. 10.1016/j.ccell.2017.11.01910.1016/j.ccell.2017.11.019 ↗
48. 10.1126/science.288.5473.205110.1126/science.288.5473.2051 ↗
49. Campbell I. G. · Cancer Res. · 1992 · 52 · 5416
50. 10.1016/j.ejca.2017.02.01310.1016/j.ejca.2017.02.013 ↗
51. 10.1016/j.immuni.2020.04.01110.1016/j.immuni.2020.04.011 ↗
52. 10.1038/386181a010.1038/386181a0 ↗
53. 10.1128/MCB.16.12.688710.1128/MCB.16.12.6887 ↗
54. 10.1083/jcb.20070804310.1083/jcb.200708043 ↗
55. 10.1146/annurev-immunol-032713-12014210.1146/annurev-immunol-032713-120142 ↗
56. 10.1016/j.cell.2009.05.04610.1016/j.cell.2009.05.046 ↗
57. 10.1016/j.cell.2009.05.04510.1016/j.cell.2009.05.045 ↗
58. 10.1038/bjc.2017.17310.1038/bjc.2017.173 ↗
59. Li Y. · Am. J. Transl. Res. · 2017 · 9 · 2901
60. 10.1016/j.cell.2010.07.04410.1016/j.cell.2010.07.044 ↗
61. 10.1038/s41591-019-0356-z10.1038/s41591-019-0356-z ↗
62. 10.1056/NEJMoa160225210.1056/NEJMoa1602252 ↗
63. 10.1155/2019/191908210.1155/2019/1919082 ↗
64. 10.1038/8533010.1038/85330 ↗
65. 10.1016/j.celrep.2018.03.02610.1016/j.celrep.2018.03.026 ↗
66. 10.1038/nature2239610.1038/nature22396 ↗
67. 10.4167/jbv.2019.49.4.23010.4167/jbv.2019.49.4.230 ↗
68. 10.1007/s11684-018-0657-510.1007/s11684-018-0657-5 ↗
69. 10.1126/sciimmunol.aay186310.1126/sciimmunol.aay1863 ↗
70. 10.1016/j.it.2016.08.01010.1016/j.it.2016.08.010 ↗
71. 10.1038/s41590-017-0004-z10.1038/s41590-017-0004-z ↗
72. 10.1002/(SICI)1521-4141(199811)28:11<3423::AID-IMMU3423>3.0.CO;2-210.1002/(SICI)1521-4141(199811)28:11<3423::AID-IMMU3423>3.0.CO;2-2 ↗
73. 10.4049/jimmunol.178.7.447310.4049/jimmunol.178.7.4473 ↗
74. 10.1038/s41586-019-1456-010.1038/s41586-019-1456-0 ↗
75. 10.1093/glycob/cwu06810.1093/glycob/cwu068 ↗
76. 10.1126/science.116898810.1126/science.1168988 ↗
77. 10.1002/jcp.2758110.1002/jcp.27581 ↗
78. 10.1016/j.immuni.2011.09.00410.1016/j.immuni.2011.09.004 ↗
79. 10.1016/S0092-8674(03)00422-710.1016/S0092-8674(03)00422-7 ↗
80. 10.1096/fj.08-10716910.1096/fj.08-107169 ↗
81. 10.1038/nature0829610.1038/nature08296 ↗
82. 10.1182/blood-2008-06-16240410.1182/blood-2008-06-162404 ↗
83. 10.1038/cdd.2016.1310.1038/cdd.2016.13 ↗
84. 10.1182/blood-2004-05-191610.1182/blood-2004-05-1916 ↗
85. 10.1016/j.immuni.2016.01.00210.1016/j.immuni.2016.01.002 ↗
86. 10.1038/nature1308510.1038/nature13085 ↗
87. 10.1038/cdd.2016.1110.1038/cdd.2016.11 ↗
88. 10.4049/jimmunol.148.7.220710.4049/jimmunol.148.7.2207 ↗
89. 10.1038/nature0958310.1038/nature09583 ↗
90. 10.1016/j.immuni.2007.11.01110.1016/j.immuni.2007.11.011 ↗
91. 10.1038/nature0632910.1038/nature06329 ↗
92. 10.1038/cdd.2014.8610.1038/cdd.2014.86 ↗
93. 10.1038/sj.cdd.440224210.1038/sj.cdd.4402242 ↗
94. 10.1182/blood-2013-09-52875210.1182/blood-2013-09-528752 ↗
95. 10.7554/eLife.0338510.7554/eLife.03385 ↗
96. 10.1038/3507560310.1038/35075603 ↗
97. 10.1002/eji.20174728310.1002/eji.201747283 ↗
98. 10.1146/annurev-immunol-032414-11210310.1146/annurev-immunol-032414-112103 ↗
99. 10.1128/MCB.01394-1310.1128/MCB.01394-13 ↗
100. 10.1038/417182a10.1038/417182a ↗